Announcements Trials

Browse Landscape

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 50 Thoracic 5 Sarcoma 3 Head & Neck 3 Gynecologic 2 Breast 2 Tumor-Agnostic 1 Other solid neoplasm 1 Endocrine 1 CNS 1

Conditions

Neoplasms 1 Carcinoma, Neuroendocrine 1

Interventions

Everolimus 27 pembrolizumab 25 Temozolomide 24 lutetium Lu 177 dotatate 22 Nivolumab 18 Magnetic Resonance Spectroscopy 18 lenvatinib 17 cabozantinib 17 Cisplatin 16 Sunitinib 15 Capecitabine 14 Bevacizumab 14 Specimen Handling 12 Sorafenib 12 trametinib 10 Ipilimumab 10 Etoposide 10 pasireotide 9 dabrafenib 9 Paclitaxel 9 Carboplatin 8 pazopanib 7 lanreotide 7 Octreotide 7 Fluorodeoxyglucose F18 7 anlotinib 6 Irinotecan 6 Injections 6 Doxorubicin 6 surufatinib 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × irinotecan sucrosofate × Endocrine × Clear all

NCT03837977 2024-12-30

NET02

The Christie NHS Foundation Trust

Phase 2 Completed

Neoplasms, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡